Susquehanna International Group
LVTX

Susquehanna International Group’s LAVA Therapeutics LVTX Stock Holding History

Susquehanna International Group’s Portfolio LVTX Stock Details LVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-118,100
Closed -$184K – 13075
2025
Q3 		$184K Buy
+118,100
New +$176K ﹤0.01% 11078
2024
Q4 		– Sell
-25,900
Closed -$43K – 12791
2024
Q3 		$43K Sell
25,900
-47,200
-65% -$86.4K ﹤0.01% 11439
2024
Q2 		$132K Buy
73,100
+55,400
+313% +$146K ﹤0.01% 10823
2024
Q1 		$58.9K Sell
17,700
-4,000
-18% -$8.8K ﹤0.01% 11492
2023
Q4 		$34.3K Buy
21,700
+4,700
+28% +$6.71K ﹤0.01% 11845
2023
Q3 		$25.3K Sell
17,000
-100
-0.6% -$179 ﹤0.01% 11538
2023
Q2 		$34.7K Buy
+17,100
New +$31.6K ﹤0.01% 11472

Susquehanna International Group's LVTX Position: Q4 2024 in Review

Susquehanna International Group sold out of LAVA Therapeutics (LVTX) in Q4 2024, closing a stake of 48,205 shares — an estimated $80K sold.

Susquehanna International Group first reported a position in LVTX in Q3 2024 and held it in 1 quarter. The position peaked at $80K in Q3 2024. 22 funds tracked by Wall St. Rank hold LVTX as of Q4 2024.

  • Susquehanna International Group reported no remaining LAVA Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Susquehanna International Group sold 48,205 LAVA Therapeutics shares in Q4 2024, an estimated $80K.
  • Susquehanna International Group first reported a position in LAVA Therapeutics in Q3 2024 and held it in 1 quarter.
  • Susquehanna International Group's LAVA Therapeutics position peaked at $80K in Q3 2024.
  • 22 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q4 2024.

Based on Susquehanna International Group's 13F filing for Q4 2024, filed 14 Feb 2025.